Approved & therapeutic
Insulin (rapid-acting analogues)
Insulin lispro, Insulin aspart, Humalog, NovoLog
Rapid-acting insulin analogues are FDA-approved peptide hormones used to control blood glucose in diabetes. They are included here because they are used non-medically in bodybuilding contexts alongside growth hormone and IGF-1 compounds, where they are among the most dangerous substances a person can self-administer.
Also known as: Humalog, NovoLog, Apidra, insulin lispro, insulin aspart, insulin glulisine, slin
- Status
- Insulin (rapid-acting analogues) is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Roughly 60 to 90 minutes for the rapid-acting analogues, with onset within 10 to 20 minutes and duration of 3 to 5 hours.
- How it's taken
- Subcutaneous injection or continuous subcutaneous infusion via pump
- Mechanism
- Metabolic (non-incretin)
- Pathways
- Insulin Signalling
How Insulin (rapid-acting analogues) works
Insulin binds the insulin receptor, driving glucose uptake into muscle and adipose tissue via GLUT4 translocation, suppressing hepatic glucose output, and promoting glycogen, lipid and protein synthesis. Rapid-acting analogues carry amino acid substitutions that prevent hexamer formation at the injection site, so they are absorbed within minutes rather than hours.
What research has looked at
- Essential, life-sustaining therapy in type 1 diabetes and widely used in type 2 diabetes.
- The rapid onset and short duration of the analogues allow mealtime dosing that approximates physiological insulin secretion far more closely than regular human insulin.
- A century of clinical use and extremely well-characterised pharmacology.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Hypoglycaemia is the defining risk and can be fatal. Severe hypoglycaemia causes seizures, permanent neurological injury, coma and death, and can develop within minutes with rapid-acting analogues.
- Non-medical use for anabolic purposes is exceptionally dangerous. There is no established safe protocol, deaths have been reported, and the risk is compounded by the practice of combining insulin with growth hormone, IGF-1 compounds and fasting states.
- Insulin requirements are altered by exercise, alcohol, illness, carbohydrate intake and other drugs — the same dose is not equally safe on different days, which is what makes fixed non-medical protocols hazardous.
- Hypokalaemia: insulin drives potassium intracellularly and can cause clinically significant, arrhythmogenic hypokalaemia.
- Weight gain, lipodystrophy at injection sites, and hypersensitivity reactions.
- It is prohibited at all times under the WADA Prohibited List for athletes without a therapeutic use exemption.
Sources
- FDA approved-drug listing for insulin lispro · U.S. Food & Drug Administration
- DailyMed prescribing information for insulin lispro · NIH · DailyMed
- PubMed research on insulin analogue hypoglycemia bodybuilding misuse · NIH · National Library of Medicine
- DrugBank record for insulin lispro · DrugBank
Track Insulin (rapid-acting analogues) in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Insulin (rapid-acting analogues) FAQ
What is Insulin (rapid-acting analogues)?
Rapid-acting insulin analogues are FDA-approved peptide hormones used to control blood glucose in diabetes. They are included here because they are used non-medically in bodybuilding contexts alongside growth hormone and IGF-1 compounds, where they are among the most dangerous substances a person can self-administer.
How does Insulin (rapid-acting analogues) work?
Insulin binds the insulin receptor, driving glucose uptake into muscle and adipose tissue via GLUT4 translocation, suppressing hepatic glucose output, and promoting glycogen, lipid and protein synthesis. Rapid-acting analogues carry amino acid substitutions that prevent hexamer formation at the injection site, so they are absorbed within minutes rather than hours.
Is Insulin (rapid-acting analogues) FDA approved?
Yes. Insulin (rapid-acting analogues) is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Insulin (rapid-acting analogues)?
Reported half-life: Roughly 60 to 90 minutes for the rapid-acting analogues, with onset within 10 to 20 minutes and duration of 3 to 5 hours.
How is Insulin (rapid-acting analogues) taken?
Subcutaneous injection or continuous subcutaneous infusion via pump.
What side effects have been reported with Insulin (rapid-acting analogues)?
Reported in the sources: Hypoglycaemia is the defining risk and can be fatal. Severe hypoglycaemia causes seizures, permanent neurological injury, coma and death, and can develop within minutes with rapid-acting analogues; Non-medical use for anabolic purposes is exceptionally dangerous. There is no established safe protocol, deaths have been reported, and the risk is compounded by the practice of combining insulin with growth hormone, IGF-1 compounds and fasting states; Insulin requirements are altered by exercise, alcohol, illness, carbohydrate intake and other drugs — the same dose is not equally safe on different days, which is what makes fixed non-medical protocols hazardous; Hypokalaemia: insulin drives potassium intracellularly and can cause clinically significant, arrhythmogenic hypokalaemia; Weight gain, lipodystrophy at injection sites, and hypersensitivity reactions; It is prohibited at all times under the WADA Prohibited List for athletes without a therapeutic use exemption.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.